A healthy market for M&A activity, particularly cross-border deals, and a strict regulatory environment are the big factors influencing the health and activities of life sciences companies. Skadden partners John T....more
1/27/2015
/ Cross-Border Transactions ,
Department of Justice (DOJ) ,
Food and Drug Administration (FDA) ,
Kickbacks ,
Life Sciences ,
Medical Devices ,
Off-Label Promotion ,
Pharmaceutical Industry ,
Popular ,
Qui Tam ,
Regulatory Standards ,
Strategic Enforcement Plan